|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with active lupus nephritis, urinary MCP-1 was significantly higher than in lupus patients studied in the inactive phase of the disease or in healthy volunteers.High doses of i.v. methylprednisolone significantly lowered urinary MCP-1 in patients with active lupus nephritis.
|
8558841 |
1995 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations suggest that MCAF is probably involved in the pathogenesis of LN with active lesions, possibly through the recruitment and activation of M phi, and that measurement of urinary MCAF levels may be a useful clinical tool for monitoring the disease activity of LN.
|
8648917 |
1996 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No association between -2518 (A/G) MCP-1 polymorphism and susceptibility to SLE nor to lupus nephritis was found.
|
11844145 |
2001 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, urinary excretion of MCP-1 was greater in AA homozygotes compared with other genotypes in patients with LN.
|
12460032 |
2002 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also showed that the MCP-1 antagonist ameliorated the initiation and progression of lupus nephritis and of renal vasculitis, which might provide a new approach to the treatment of the disease.
|
13130475 |
2003 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we assessed the significance of the MCP-1 gene in determination of the histological phenotype in lupus nephritis.
|
15119544 |
2004 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined the role of a functional monocyte chemoattractant protein 1 (MCP-1) polymorphism in SLE and LN.
|
15188361 |
2004 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
In this study, we examined the role of a functional monocyte chemoattractant protein 1 (MCP-1) polymorphism in SLE and LN.
|
15188361 |
2004 |
|
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Larger prospective studies of paediatric LN are required to further evaluate MCP-1 and other markers of disease progression.
|
18495743 |
2008 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incubating IL-20 with mesangial cells upregulated the transcripts of CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10), IL-6, iNOS, and ROS, all of which are involved in the pathogenesis of lupus nephritis.
|
18771958 |
2008 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis on 3419 subjects indicates that no association exists between the MCP-1 -2518 A/G polymorphism and SLE or LN.
|
19941075 |
2010 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support that MCP-1 -2518 G/G is associated with LN but there was no association of this genotype with renal function or renal survival.
|
20231199 |
2010 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to evaluate the possible association of the polymorphism -2518 of the MCP-1 gene with the risk of developing SLE, manifesting lupus nephritis (LN) and with other clinical features of SLE in an Argentinean population.
|
22466290 |
2012 |
|
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mizoribine itself selectively attenuated the expression of MCP-1 both mRNA and protein levels in MCs treated with poly IC; that is, a possible model of 'pseudoviral' infection, which may be involved in the pathogenesis of lupus nephritis.
|
24134561 |
2014 |
|
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, overexpression of CCL2 in lupus MSCs restored their immunoregulatory ability for B cells in vitro and ameliorated the pathology of lupus nephritis and serological changes in MRL/lpr mice in vivo.
|
25339674 |
2014 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urinary HER-2 was increased in LN and reflected disease activity, and its levels correlated with those of 2 other recognized LN biomarkers, MCP-1 and VCAM-1.
|
26016809 |
2015 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients.
|
26429331 |
2015 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual blockade of CCL2 and CXCL12 can be as potent as CYC to suppress the progression of proliferative lupus nephritis probably because the respective chemokine targets mediate different disease pathomechanisms, i.e. systemic autoimmunity and peripheral tissue inflammation.
|
27392463 |
2016 |
|
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Urinary AGP, ceruloplasmin, VCAM-1, MCP-1 and LPGDS levels were significantly higher in those patients with active LN than in non-LN patients [all corrected p values (p <sub>c</sub>) < 0.05] across both cohorts.
|
27590021 |
2017 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Objectives The renal activity index for lupus (RAIL) score was developed in children with lupus nephritis as a weighted sum of six urine biomarkers (UBMs) (neutrophil gelatinase-associated lipocalin, monocyte chemotactic protein 1, ceruloplasmin, adiponectin, hemopexin and kidney injury molecule 1) measured in a random urine sample.
|
28361601 |
2017 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether levels of urinary neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein 1 (MCP-1) are good biomarkers to differentiate patients with lupus nephritis among Latin-American systemic lupus erythematosus (SLE) patients.
|
29073812 |
2018 |
|
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual blockade of CCL2 and CXCL12 can be as potent as CYC to suppress the progression of proliferative lupus nephritis probably because the respective chemokine targets mediate different disease pathomechanisms, i.e. systemic autoimmunity and peripheral tissue inflammation.
|
29111236 |
2017 |
|
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of monocyte chemoattractant protein-1 (MCP-1) in the serum and urine of 72 SLE patients (27 with LN and 45 without LN involvement) and 30 healthy individuals were studied to establish their clinical significance.
|
29181621 |
2018 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis suggests that the MCP-1-2518A/G polymorphism is associated with an increased risk of LN, especially in the American population.
|
29390552 |
2017 |
|
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A combined model of uMCP-1 and uTWEAK showed an AUC of 0.887, sensitivity of 86.67% and specificity of 80.00% to discriminate active LN, and an AUC of 0.778, sensitivity of 75.00% and specificity of 81.82% to discriminate LN with poor outcome, which are better than the utility of any markers individually.
|
29451067 |
2018 |